ACLS Provider: Course

Incorrect. A 30:2 ratio ensures adequate oxygenation and circulation when no advanced airway is present.

Incorrect. A compression fraction above 80% ensures that most of the resuscitation time is spent performing chest compressions.

Incorrect. Hypovolemia is a reversible cause of cardiac arrest that can be treated with fluid resuscitation to restore circulation.

Incorrect. The compression-to-ventilation ratio for single-rescuer infant CPR is 30:2, ensuring sufficient oxygenation and circulation.

Incorrect. Adenosine is used to terminate stable narrow-complex tachycardia by slowing AV node conduction.

Incorrect. Dopamine is used when atropine is ineffective, improving heart rate and contractility by stimulating beta receptors.

Incorrect. A compression fraction >80% is required to maximize perfusion and improve survival rates during high-quality CPR.

Incorrect. Epinephrine is administered after defibrillation to enhance coronary and cerebral perfusion during resuscitation.

Incorrect. These shockable rhythms require immediate defibrillation to restore a perfusing rhythm.

Incorrect. Epinephrine is given as a continuous infusion to maintain adequate heart rate and perfusion when atropine is ineffective.

Incorrect. Epinephrine is administered every 3-5 minutes during pediatric cardiac arrest to enhance coronary and cerebral perfusion.

Incorrect. IO access provides a reliable alternative for rapid drug delivery during resuscitation when IV access cannot be obtained.

Incorrect. PEA is treated with CPR, epinephrine, and identifying reversible causes to restore organized electrical activity.

Incorrect. A PETCO2 reading above 10 mmHg indicates adequate chest compressions and cardiac output during CPR.

Incorrect. For unstable narrow, irregular tachycardias, synchronized cardioversion at 120-200 J is recommended.

Incorrect. Amiodarone is administered as a 300 mg IV/IO bolus for refractory VF or pulseless VT.

Incorrect. Optimal for maintaining adequate circulation without risking poor perfusion due to excessive speed.

Incorrect. Biphasic defibrillators deliver effective shocks within the range of 120-200 J to treat VF or pulseless VT.

Incorrect. Adenosine is contraindicated in unstable patients; synchronized cardioversion is the treatment of choice in such cases.

Incorrect. Minimizing interruptions to less than 10 seconds preserves perfusion and improves resuscitation outcomes.

Incorrect. The compression fraction should be greater than 80% to maximize perfusion during CPR.

Incorrect. Waveform capnography provides real-time confirmation of ET tube placement and ensures proper ventilation.

Incorrect. Administered every 3-5 minutes to restore circulation by increasing coronary and cerebral perfusion pressure.

Incorrect. Compressing to a depth of 2-2.4 inches ensures adequate circulation without causing damage to internal organs.

Incorrect. A sudden increase in PETCO2 is a reliable indicator of ROSC, reflecting improved circulation and gas exchange.

Incorrect. Maintaining oxygen saturation at 92-96% prevents hypoxia and avoids complications associated with hyperoxia.

Incorrect. Epinephrine is repeated every 3-5 minutes during cardiac arrest to enhance perfusion pressure.

Incorrect. Epinephrine at 0.01 mg/kg IV/IO is administered every 3-5 minutes to enhance coronary and cerebral perfusion in children.

Incorrect. Synchronized cardioversion is used for unstable atrial fibrillation to restore organized electrical activity.

Incorrect. Oxygen levels should be monitored and optimized to maintain saturation within the target range of 92-96%.

Incorrect. PEA is not a shockable rhythm; it is managed with high-quality CPR and addressing the underlying reversible causes.

Incorrect. Ventilation with an advanced airway should be provided at a rate of 1 breath every 6 seconds, or 10 breaths per minute.

Incorrect. Pulseless VT is treated with defibrillation, while synchronized cardioversion is reserved for tachyarrhythmias with a pulse.

Incorrect. PETCO2 monitoring provides continuous feedback on the quality of chest compressions and the effectiveness of resuscitation.

Incorrect. High-quality CPR is the primary treatment for asystole, along with epinephrine and addressing reversible causes.

Incorrect. Adenosine is used to terminate reentrant arrhythmias in narrow-complex SVT by slowing conduction through the AV node.

Incorrect. Asystole is not a shockable rhythm; it is treated with high-quality CPR and epinephrine.

Incorrect. If VF persists after defibrillation and epinephrine, amiodarone is administered to stabilize the rhythm.

Incorrect. The jaw thrust maneuver opens the airway without moving the cervical spine, reducing the risk of spinal injury.

Incorrect. Pulseless VT is a shockable rhythm that requires immediate defibrillation to restore a perfusing rhythm.

Incorrect. Magnesium sulfate is used to treat torsades de pointes but is not the first-line drug for VF, where epinephrine is prioritized.

Incorrect. Ventricular fibrillation (VF) is a shockable rhythm and requires immediate defibrillation to restore an organized rhythm.

Incorrect. Adenosine is the first-line drug for treating narrow-complex SVT by slowing conduction through the AV node.

Incorrect. Magnesium sulfate stabilizes the myocardium and is the drug of choice for torsades de pointes.

Incorrect. Adenosine is used for narrow-complex SVT, not wide-complex tachycardia, which is typically treated with amiodarone.

Incorrect. Delivering 1 breath every 5-6 seconds prevents hypoventilation or hyperventilation.

Incorrect. Requires immediate defibrillation to restore organized cardiac activity.

Incorrect. IM epinephrine is the first-line treatment for anaphylaxis, administered into the mid-thigh for rapid absorption.

Incorrect. Delivering 6-8 breaths per minute minimizes interruptions in chest compressions and prevents hyperventilation.

Incorrect. Adenosine is administered at 0.1 mg/kg as a rapid IV push for terminating narrow-complex SVT caused by reentrant pathways.

Incorrect. Pulseless VT is a shockable rhythm requiring immediate defibrillation to restore organized cardiac activity.

Incorrect. For biphasic defibrillators, 120-200 J is the recommended energy range for VF.

Incorrect. Pediatric defibrillation starts at 2 J/kg for the initial shock, increasing as needed based on the patient's response.

Incorrect. A 15:2 ratio ensures efficient oxygenation and circulation in pediatric patients during two-rescuer CPR.

Incorrect. Delivers an electrical shock to depolarize the heart and restore a normal rhythm.

Incorrect. Atropine blocks vagal stimulation, increasing heart rate in cases of symptomatic bradycardia.

Incorrect. With an advanced airway, compressions continue uninterrupted while ventilation is provided at a rate of 10 breaths per minute.

Incorrect. Magnesium sulfate stabilizes cardiac myocytes and is the drug of choice for treating torsades de pointes.

Incorrect. Epinephrine is dosed at 0.01 mg/kg IV/IO during pediatric cardiac arrest to improve coronary and cerebral perfusion.

Incorrect. This rate ensures effective circulation without causing inadequate ventricular filling.

Incorrect. Epinephrine is given every 3-5 minutes to enhance coronary and cerebral perfusion during cardiac arrest.

Incorrect. PETCO2 monitoring ensures effective ventilation and provides feedback on the quality of chest compressions during CPR.

Incorrect. Asystole is a non-shockable rhythm requiring immediate CPR and epinephrine administration.

Incorrect. PEA is treated with epinephrine and high-quality CPR to address underlying reversible causes.

Incorrect. Amiodarone is preferred, but lidocaine is an alternative antiarrhythmic for refractory VF or pulseless VT.